Tuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Early and accurate diagnosis of active TB is critical to both enhance patient care, improve patient outcomes, and break Mycobacterium tuberculosis (Mtb) transmission cycles. Angiopoietin-like 4 (Angptl4) is a protein that belongs to the angiopoietin-like family. Angptl4 promotes the recruitment of immune cells and the production of inflammatory cytokines, contributing to the modulation of inflammatory processes. It can be induced by pro-inflammatory signals, such as tumor necrosis factoralpha (TNF-α), interleukin-1 beta (IL-1β), and lipopolysaccharides (LPS). Given its multifaceted roles in metabolic disorders, angiogenesis, and inflammation, Angptl4 has attracted attention as a potential therapeutic target. In this study, using western blot and RT-PCR, the expression level of ANGPTL4, IL-6, Sirt1, NF-κB, TNF-α, JNK-MAPK and IL-1β in patients with tuberculosis (50 people) and healthy people were measured. Expression level of ANGPTL4, IL-6, NF-κB, TNF-α, JNK-MAPK and IL-1β increased significantly (P < 0.05) in patients compared to the control (healthy group) and the amount of Sirt1 decreased. The results of our study show that the identification of specific immunological markers and their association with ANGPTL4 expression can lead to the discovery of new diagnostic biomarkers for tuberculosis. These biomarkers can be used to improve the accuracy and efficiency of TB diagnosis, especially in resource-limited settings where traditional diagnostic methods may be limited.